Lykos Therapeutics
American public benefit pharmaceutical company developing psychedelic-assisted therapies
Resilient Pharmaceuticals, formerly known as Lykos Therapeutics and before that as the MAPS Public Benefit Corporation, is a public benefit corporation (PBC) developing MDMA ("ecstasy") for potential medicinal use. It was founded and is part-owned by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS PBC was founded in 2014 and was renamed to Lykos Therapeutics in January 2024, then to Resilient Pharmaceuticals in August 2025.